References
[1] June Ereo-Orbea, et al. Structural Basis of Enhanced Crystallizability Induced by a Molecular Chaperone for Antibody Antigen-Binding Fragments. J Mol Biol. 2018 Feb 2;430(3):322-336 DOI:
10.1016/j.jmb.2017.12.010[2] Shang-Fan Yu, et al. An Anti-CD22- seco-CBI-Dimer Antibody-Drug Conjugate (ADC) for the Treatment of Non-Hodgkin Lymphoma That Provides a Longer Duration of Response than Auristatin-Based ADCs in Preclinical Models. Mol Cancer Ther. 2021 Feb;20(2):340-346. DOI:
10.1158/1535-7163.MCT-20-0046
